Metraipolis › archive › dc_11bdd4cb9ded

Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine — Europe PMC PMID:41827159

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41827159
DOI
10.3390/jcm15051742
License (as archived)
solo-consultazione
Archived
2026-11-05T12:16:17.515Z
SHA-256 of the archived text
1a827d0f07dcfc9076591662186cd4d218a381220c608446ae83f096a0b803f5
Stable URL of this page
https://metraipolis.com/documento/dc_11bdd4cb9ded

How to cite

Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine — Europe PMC PMID:41827159 — Europe PMC (en), https://europepmc.org/article/MED/41827159 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_11bdd4cb9ded (Metraipolis archive dc_11bdd4cb9ded, sha256 1a827d0f07dcfc9076591662186cd4d218a381220c608446ae83f096a0b803f5)
BibTeX
@misc{dc11bdd4cb9ded,
  title = {Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine — Europe PMC PMID:41827159},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41827159},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_11bdd4cb9ded; sha256 1a827d0f07dcfc9076591662186cd4d218a381220c608446ae83f096a0b803f5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41827159. Agents can read the archived copy with the MCP tool read_document.